Design, Synthesis and biochemical evaluation of novel anthracenes, ethanoanthracenes and related compounds to target Burkitt's Lymphoma
Citation:
Andrew J. Byrne, 'Design, Synthesis and biochemical evaluation of novel anthracenes, ethanoanthracenes and related compounds to target Burkitt's Lymphoma', [thesis], Trinity College (Dublin, Ireland). School of Pharmacy & Pharmaceutical Sciences, 2015, pp 466Abstract:
Burkitt's lymphoma is an aggressive non-Hodgkin lymphoma occurring with high
incidence in developing areas such as equatorial Africa and Papua New Guinea. Within these
tropical regions of high incidence (40-50 per 10 6), Burkitt's lymphoma accounts for
approximately 50% of childhood cancers and up to 90% of childhood lymphomas diagnosed.
The treatment of Burkitt's lymphoma in these regions is insufficient and the development of
new, safe and cost effective therapeutics are of current interest. Previous work within the
Meegan and Williams groups in Trinity College Dublin identified a potent apoptotic effect
induced by the (E)-1,3-bis(aryl)-2-nitro-1-propenes and the tetracyclic antidepressant
maprotiline in Burkitt's lymphoma cell lines (MUTU-I and DG-75).
Author: Byrne, Andrew J.
Advisor:
Meegan, MaryQualification name:
Doctor of Philosophy (Ph.D.)Publisher:
Trinity College (Dublin, Ireland). School of Pharmacy & Pharmaceutical SciencesNote:
TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ieType of material:
thesisCollections
Availability:
Full text availableMetadata
Show full item recordLicences: